Glycemic Control Status and Long-Term Clinical Outcomes in Diabetic Chronic Total Occlusion Patients: An Observational Study

Table 3

Estimated Kaplan–Meier events rates in propensity score-matched population.

	HbA1c < 7.0	HbA1c ≥ 7.0	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
MACE	119 (33.7)	140 (39.7)	1.422 (1.027–1.970)	1.531 (1.009–2.149)
Cardiac death	17 (4.8)	15 (4.2)	0.913 (0.434–1.921)	0.717 (0.324–1.584)
Repeat revascularization	99 (28.0)	123 (34.8)	1.618 (1.111–2.356)	1.828 (1.238–2.698)
Repeat nonfatal MI	21 (5.9)	16 (4.5)	0.582 (0.268–1.261)	0.513 (0.235–1.119)
All-cause death	24 (6.8)	23 (6.5)	1.044 (0.561–1.943)	0.878 (0.457–1.687)
TVR	57 (16.1)	76 (21.5)	1.595 (0.957–2.657)	1.668 (0.994–2.796)

Adjusted covariates: age, CKD, LAD-CTO, LCX-CTO, LVEF, PVD, Rentrop grade ≥ 2, RWMA, sex, single-vessel disease, systolic heart failure, SYNTAX score, and triple-vessel disease. CKD: chronic kidney disease; CI: conference interval; HR: hazard ratio; LAD-CTO: left anterior descending artery-chronic total occlusion; LCX-CTO: left circumflex chronic total occlusion; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac events, a composite of cardiac death, repeat revascularization, and repeat nonfatal MI; MI: myocardial infarction; PVD: peripheral vascular disease; RWMA: regional wall motion abnormalities; SYNTAX: percutaneous coronary intervention with taxus and cardiac surgery; TVR: target vessel revascularization.